CD19 and neuroblastoma: For example, CAR γδ T cells targeting GD2, CD19, and NKG2D ligands have shown potent antitumor activity in xenograft models of neuroblastoma, leukemia, and solid tumors, often with reduced risk of graft-versus-host disease compared with αβ T cells [126,127,128].